
Co-Diagnostics (CODX) Stock Forecast & Price Target
Co-Diagnostics (CODX) Analyst Ratings
Bulls say
Co-Diagnostics Inc is positioned positively due to its innovative proprietary technologies that simplify and reduce the cost of molecular diagnostics, particularly through the development of a new sample preparation instrument for point-of-care PCR testing. The company's strategic international presence, including joint ventures and manufacturing capabilities, enhances its potential to scale operations and expand access to affordable diagnostics in underserved regions. Additionally, ongoing advancements in regulatory pathways for the Co-Dx PCR platform and the company's commitment to addressing broader diagnostic challenges indicate a strong foundational support for future growth opportunities.
Bears say
Co-Diagnostics Inc. is facing a negative outlook primarily due to a significant reduction in its projected price target, which has declined from $10.00 to $3.00 based on revised assumptions regarding its financial performance. With a cash balance of $11 million, the company is projected to incur quarterly expenses of $5-7 million, which raises concerns about its financial sustainability and suggests that upcoming capital raises may lead to further dilution and unfavorable terms. Additionally, trading below $1.00 adds pressure to the company’s ability to secure necessary financing, potentially leading to a downward financing spiral that could further harm its market valuation.
This aggregate rating is based on analysts' research of Co-Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Co-Diagnostics (CODX) Analyst Forecast & Price Prediction
Start investing in Co-Diagnostics (CODX)
Order type
Buy in
Order amount
Est. shares
0 shares